Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F] Fluciclatide PET/CT in Renal Cancer
NCT01633255Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Apr 2012
- Primary completion
- Apr 2014
01
Overview
A Phase 2 trial of fluciclatide in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Planned start Apr 2012; status: withdrawn.
02
Drugs
fluciclatide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01633255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01633255.